Angiogenesis in Waldenstrom's macroglobulinemia

Seminars in Oncology

Volumn 30, Issue 2, 2003, Pages 262-264

  Rajkumar, S Vincent ^a   Hayman, Suzanne ^a   Greipp, Philip R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; CYTOKINE;

ANGIOGENESIS; ARTICLE; BONE MARROW METASTASIS; CANCER SURVIVAL; CAPILLARY DENSITY; HEMATOLOGIC DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; PARACRINE SIGNALING; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0037396141     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.50071     Document Type: Article

References (19)

1. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
2. Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763, 1995
3. Fox SB: Tumour angiogenesis and prognosis. Histopathology 30:294-301, 1997
4. Boehm T, Folkman J, Browder T, et al: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407, 1997
5. Aguayo A, Kantarjian H, Manshouri T, et al: Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96:2240-2245, 2000
6. Vacca A, Ribatti D, Roncali L, et al: Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leuk Lymphoma 20:27-38, 1995
7. Rajkumar SV, Fonseca R, Witzig TE, et al: Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 13:469-472, 1999
8. Rajkumar SV, Mesa RA, Fonseca R, et al: Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 8:2210-2216, 2002
9. Vacca A, Ribatti D, Roncali L, et al: Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87:503-508, 1994
10. Vacca A, Ribatti D, Presta M, et al: Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93:3064-3073, 1999
11. Rajkumar SV, Leong T, Roche PC, et al: Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6:3111-3116, 2000
12. Sezer O: Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 79:574-577, 2000
13. Kumar S, Fonseca R, Dispenzieri A, et al: Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood (in press)
14. Bellamy WT, Richter L, Frutiger Y, et al: Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59:728-733, 1999
15. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
17. Rajkumar SV, Fonseca R, Dispenzieri A, et al: Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 75:897-902, 2000
18. Kneller A, Raanani P, Hardan I, et al: Therapy with thalidomide in refractory multiple myeloma - The revival of an old drug. Br J Haematol 108:391-393, 2000
19. Dankbar B, Padro T, Leo R, et al: Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95:2630-2636, 2000